Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock-induced seizure model and chimney test in mice

Epilepsy Research

Volumn 108, Issue 10, 2014, Pages 1728-1733

  Florek Luszczki, Magdalena ^a   Zagaja, Miroslaw ^a   Luszczki, Jarogniew J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cannabinoids; Chimney test; Clobazam; Lacosamide; Maximal electroshock induced seizures; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CLOBAZAM; HARKOSERIDE; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BENZOXAZINE DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHIMNEY TEST; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG POTENTIATION; ELECTROSHOCK SEIZURE; MALE; MEDICAL PARAMETERS; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTECTIVE INDEX; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ELECTRIC SHOCK; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR ACTIVITY; PATHOPHYSIOLOGY; RANDOMIZATION; SEIZURES;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; BENZOXAZINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROSHOCK; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; RANDOM ALLOCATION; SEIZURES;

EID: 84913554913     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.10.004     Document Type: Article

References (39)

1. Andres-Mach M., Haratym-Maj A., Zagaja M., Luszczki J.J. Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model-an isobolographic analysis for parallel dose-response relationship curves. Pharmacology 2014, 93:172-177.
2. Bender R.A., Baram T.Z. Epileptogenesis in the developing brain: what can we learn from animal models?. Epilepsia 2007, 5:2-6.
3. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basle) 1960, 3:81-84.
4. Choi D., Stables J.P., Kohn H. The anticonvulsant activities of functionalized N-benzyl 2-acetamidoacetamides. The importance of the 2-acetamido substituent. Bioorg. Med. Chem. 1996, 4:2105-2114.
5. Choi D., Stables J.P., Kohn H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 1996, 39:1907-1916.
6. Doi T., Ueda Y., Tokumaru J., Willmore L.J. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res. Mol. Brain Res. 2005, 142:91-96.
7. Doty P., Hebert D., Mathy F.X., Byrnes W., Zackheim J., Simontacchi K. Development of lacosamide for the treatment of partial-onset seizures. Ann. N.Y. Acad. Sci. 2013, 1291:56-68.
8. Errington A.C., Coyne L., Stohr T., Selve N., Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50:1016-1029.
9. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73:157-169.
10. Florek-Luszczki M., Wlaz A., Kondrat-Wrobel M.W., Tutka P., Luszczki J.J. Effects of WIN 55,212-2 (a non-selective cannabinoid CB and CB receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6Hz psychomotor seizure model. J. Neural Transm. 2014, 19:19.
11. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 8:63-68.
12. Giarratano M., Standley K., Benbadis S.R. Clobazam for treatment of epilepsy. Exp. Opin. Pharmacother. 2012, 13:227-233.
13. Grosso S., Coppola G., Cusmai R., Parisi P., Spalice A., Foligno S., Verrotti A., Balestri P. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome. Acta Neurol. Scand. 2014, 129:420-424.
14. Hao X., Goldberg D., Kelly K., Stephen L., Kwan P., Brodie M.J. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013, 29:4-6.
15. Hofler J., Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013, 54:393-404.
16. Jensen H.S., Nichol K., Lee D., Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for alpha(2)- versus alpha(1)-GABA(A)-receptor complexes. PLoS One 2014, 9:1-8. e88456.
17. Kovacs F.E., Knop T., Urbanski M.J., Freiman I., Freiman T.M., Feuerstein T.J., Zentner J., Szabo B. Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. Neuropsychopharmacology 2012, 37:1104-1114.
18. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N. Engl. J. Med. 2011, 365:919-926.
19. LeTiran A., Stables J.P., Kohn H. Design and evaluation of affinity labels of functionalized amino acid anticonvulsants. J. Med. Chem. 2002, 45:4762-4773.
20. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
21. Loscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8:79-94.
22. Loscher W., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res. 1991, 9:1-10.
23. Luk M.E., Tatum W.O., Patel A.V., Nau K.M., Freeman W.D. The safety of lacosamide for treatment of seizures and seizure prophylaxis in adult hospitalized patients. Neurohospitalist 2012, 2:77-81.
24. Luszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2009, 602:298-305.
25. Luszczki J.J., Czuczwar S.J. Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur. Neuropsychopharmacol. 2005, 15:133-142.
26. Luszczki J.J., Misiuta-Krzesinska M., Florek M., Tutka P., Czuczwar S.J. Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol. Biochem. Behav. 2011, 98:261-267.
27. Luszczki J.J., Ratnaraj N., Patsalos P.N., Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 373:169-181.
28. Luszczki J.J., Wlaz A., Karwan S., Florek-Luszczki M., Czuczwar S.J. Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 2013, 720:247-254.
29. Naderi N., Aziz Ahari F., Shafaghi B., Najarkolaei A.H., Motamedi F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J. Neural Transm. 2008, 115:1501-1511.
30. Ng Y.T., Collins S.D. Clobazam. Neurother. 2007, 4:138-144.
31. Owen R.T. The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome. Drugs Today 2012, 48:697-703.
32. Shandra A., Shandra P., Kaschenko O., Matagne A., Stohr T. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia 2013, 54:1167-1175.
33. St Louis E.K. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr. Neuropharmacol. 2009, 7:96-105.
34. Stafstrom C.E., Sutula T.P. Models of epilepsy in the developing and adult brain: implications for neuroprotection. Epilepsy Behav. 2005, 7:19.
35. Stephen L.J., Brodie M.J. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr. Opin. Neurol. 2012, 25:164-172.
36. Stephen L.J., Forsyth M., Kelly K., Brodie M.J. Antiepileptic drug combinations-have newer agents altered clinical outcomes?. Epilepsy Res. 2012, 98:194-198.
37. Stohr T., Kupferberg H.J., Stables J.P., Choi D., Harris R.H., Kohn H., Walton N., White H.S. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007, 74:147-154.
38. Wasterlain C.G., Baldwin R., Naylor D.E., Thompson K.W., Suchomelova L., Niquet J. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia 2011, 8:70-71.
39. Yang L.P., Scott L.J. Clobazam: in patients with Lennox-Gastaut syndrome. CNS Drugs 2012, 26:983-991.